Corient Private Wealth LLC Has $9.05 Million Holdings in Laboratory Co. of America Holdings (NYSE:LH)

Corient Private Wealth LLC decreased its holdings in shares of Laboratory Co. of America Holdings (NYSE:LH) by 0.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 39,809 shares of the medical research company’s stock after selling 240 shares during the quarter. Corient Private Wealth LLC’s holdings in Laboratory Co. of America were worth $9,048,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in LH. Manchester Capital Management LLC raised its stake in shares of Laboratory Co. of America by 1.1% during the 4th quarter. Manchester Capital Management LLC now owns 4,159 shares of the medical research company’s stock worth $945,000 after purchasing an additional 45 shares in the last quarter. Trust Investment Advisors raised its position in Laboratory Co. of America by 1.8% during the fourth quarter. Trust Investment Advisors now owns 2,567 shares of the medical research company’s stock worth $583,000 after acquiring an additional 46 shares in the last quarter. SP Asset Management LLC lifted its stake in Laboratory Co. of America by 0.3% in the fourth quarter. SP Asset Management LLC now owns 14,992 shares of the medical research company’s stock valued at $3,407,000 after acquiring an additional 46 shares during the last quarter. Atria Wealth Solutions Inc. grew its position in shares of Laboratory Co. of America by 2.8% in the 4th quarter. Atria Wealth Solutions Inc. now owns 1,969 shares of the medical research company’s stock valued at $448,000 after acquiring an additional 53 shares during the period. Finally, Caprock Group LLC increased its stake in shares of Laboratory Co. of America by 1.8% during the 4th quarter. Caprock Group LLC now owns 3,084 shares of the medical research company’s stock worth $701,000 after purchasing an additional 56 shares during the last quarter. Institutional investors own 95.94% of the company’s stock.

Laboratory Co. of America Trading Up 1.7 %

Shares of Laboratory Co. of America stock opened at $199.65 on Friday. The company has a debt-to-equity ratio of 0.39, a quick ratio of 0.76 and a current ratio of 0.88. The firm has a 50-day moving average of $207.09 and a 200-day moving average of $215.15. Laboratory Co. of America Holdings has a 52-week low of $174.20 and a 52-week high of $234.09. The stock has a market cap of $16.83 billion, a PE ratio of 40.17, a PEG ratio of 1.50 and a beta of 1.02.

Laboratory Co. of America (NYSE:LH) last posted its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.48 by $0.20. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The firm had revenue of $3.18 billion during the quarter, compared to the consensus estimate of $3.12 billion. During the same quarter in the previous year, the firm posted $3.82 EPS. The business’s revenue for the quarter was up 4.6% compared to the same quarter last year. As a group, sell-side analysts forecast that Laboratory Co. of America Holdings will post 14.87 EPS for the current year.

Laboratory Co. of America Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Shareholders of record on Tuesday, May 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, May 24th. This represents a $2.88 dividend on an annualized basis and a yield of 1.44%. Laboratory Co. of America’s dividend payout ratio (DPR) is presently 57.95%.

Insider Buying and Selling at Laboratory Co. of America

In other news, CAO Peter J. Wilkinson sold 2,439 shares of the stock in a transaction on Monday, April 29th. The stock was sold at an average price of $204.33, for a total transaction of $498,360.87. Following the sale, the chief accounting officer now directly owns 2,087 shares of the company’s stock, valued at approximately $426,436.71. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other Laboratory Co. of America news, CMO Amy B. Summy sold 227 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The shares were sold at an average price of $218.45, for a total transaction of $49,588.15. Following the completion of the transaction, the chief marketing officer now directly owns 3,859 shares in the company, valued at $842,998.55. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Peter J. Wilkinson sold 2,439 shares of the firm’s stock in a transaction on Monday, April 29th. The shares were sold at an average price of $204.33, for a total value of $498,360.87. Following the completion of the sale, the chief accounting officer now directly owns 2,087 shares in the company, valued at approximately $426,436.71. The disclosure for this sale can be found here. Insiders sold 23,744 shares of company stock valued at $5,111,382 in the last three months. Corporate insiders own 0.85% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on LH. Argus upgraded shares of Laboratory Co. of America from a “hold” rating to a “buy” rating and set a $250.00 target price for the company in a research note on Monday, March 25th. Robert W. Baird cut their price objective on Laboratory Co. of America from $255.00 to $244.00 and set an “outperform” rating for the company in a research report on Friday, April 26th. Barclays decreased their target price on Laboratory Co. of America from $234.00 to $213.00 and set an “equal weight” rating on the stock in a report on Friday, April 26th. SVB Leerink began coverage on Laboratory Co. of America in a report on Monday, February 26th. They set an “outperform” rating and a $260.00 price target for the company. Finally, Leerink Partnrs reiterated an “outperform” rating on shares of Laboratory Co. of America in a report on Monday, February 26th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, Laboratory Co. of America currently has an average rating of “Moderate Buy” and a consensus price target of $243.14.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).